Kento Inoue
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kento Inoue has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Akira Nishimura
11Department of Pediatrics and Developmental Biology, Institute of Science Tokyo, Tokyo, Japan
1 shared publication - Dan Tomomasa
Institute of Science Tokyo 1 Department of Pediatrics and Developmental Biology Tokyo
1 shared publication - Hans Dietrich Ochs
Center for Immunity and Immunotherapies, Seattle Children's Research Institute, University of Washington. Seattle, Wash
1 shared publication - Hirokazu Kanegane
Department of Child Health and Development, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan
1 shared publication - Kay Tanita
Graduate School of Medical and Dental Sciences, Institute of Science Tokyo 2 Department of Pediatrics and Developmental Biology Tokyo
1 shared publication - Madoka Nishimura
Graduate School of Medical and Dental Sciences, Institute of Science Tokyo 1 Department of Pediatrics and Developmental Biology Tokyo
1 shared publication
Latest Publications
- Open Access
- 28 April 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (1)
Revisiting X-linked agammaglobulinemia
Discovered >70 years ago by Ogden Bruton, X-linked agammaglobulinemia (XLA), characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and peripheral blood B-cell deficiency, is among the best-established inborn errors of immunity (IEIs) and one of the most well-documented single types of IEIs, the incidence of which is estimated to be between 1:100,000 and 1:200,000. However, although the pathogenesis of XLA is well understood, several issues remain open for discussion. In this review, we describe several unresolved issues, including noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, noninfectious neurodegeneration, renal involvement, and malignancies. The primary treatment for XLA, immunoglobulin replacement therapy, administered either intravenously or subcutaneously, has remained unchanged since its discovery. Allogeneic hematopoietic cell transplantation has been successful in some XLA patients, but there are still few reports. However, it may be considered as a treatment option in the future. Given that XLA is one of the most common types of IEIs, resolving these issues is a priority.
- 28 April 2025
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 1 (1)
Open AccessRevisiting X-linked agammaglobulinemia
Discovered >70 years ago by Ogden Bruton, X-linked agammaglobulinemia (XLA), characterized by recurrent bacterial infections, hypo/agammaglobulinemia, and peripheral blood B-cell deficiency, is among the best-established inborn errors of immunity (IEIs) and one of the most well-documented single types of IEIs, the incidence of which is estimated to be between 1:100,000 and 1:200,000. However, although the pathogenesis of XLA is well understood, several issues remain open for discussion. In this review, we describe several unresolved issues, including noncoding BTK variants, contiguous deletion syndrome, Helicobacter infection, noninfectious neurodegeneration, renal involvement, and malignancies. The primary treatment for XLA, immunoglobulin replacement therapy, administered either intravenously or subcutaneously, has remained unchanged since its discovery. Allogeneic hematopoietic cell transplantation has been successful in some XLA patients, but there are still few reports. However, it may be considered as a treatment option in the future. Given that XLA is one of the most common types of IEIs, resolving these issues is a priority.